Glenmark Pharma acquires OTC drugs for US market from Wockhardt

Mumbai-based Glenmark Pharmaceuticals has acquired approved Abbreviated New Drug Applications (ANDAs) for Famotidine Tablets USP, 10 mg and 20 mg (OTC), Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg (OTC), Lansoprazole DelayedRelease Capsules USP, 15 mg (OTC) and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) in the US from fellow publicly-listed Wockhardt Ltd.